（於中華人民共和國註冊成立的股份有限公司） 股份代號：6127 香港聯交所環境、社會及管治報告守則內容索引 48 關於本報告 本報告為北京昭衍新藥研究中心股份有限公司（下稱「公司」、「本公司」、「昭衍新藥」或「我們」）發佈的第五份《社會責任 暨環境、社會及管治報告》，本報告主要介紹本公司在環境、社會及管治方面的管理政策和履責實踐。 報告期及主體範圍 本報告披露本公司從2024年1月1日起至2024年12月31日止（下稱「本年度」或「報告期內」），於環境、社會和管治方面的 管理方法、舉措及績效表現（部分內容追溯至以前年度或延伸至本報告披露日）。除環境數據外，本報告所披露內容範 圍與年報相同，為本公司所有分子公司。相比上一期報告，本報告環境數據的統計範圍增加三家子公司，包括：雲南 英茂生物科技有限公司、廣西瑋美生物科技有限公司及Biomedical Research Models, Inc（以下簡稱「Biomere」）。 報告主要參照標準 本報告參照《上海證券交易所上市公司自律監管指引第14號－可持續發展報告（試行）》、香港聯合交易所有限公司（以下 簡稱「香港聯交所」）主板上市規則附錄C2所載之《環境、社會及管治 ...

Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching RMB 1.2 billion for the fiscal year 2024[2]. - Revenue for the year ended December 31, 2024, was RMB 2,018,334 thousand, a decrease of 15.06% compared to RMB 2,376,487 thousand in 2023[17]. - Gross profit for 2024 was RMB 505,540 thousand, reflecting a gross margin of 25.05%, down from 41.21% in 2023[17]. - Net profit for the year was RMB 69,755 thousand, a significant decline of 82.16% from RMB 391,553 thousand in 2023[17]. - Total assets as of December 31, 2024, amounted to RMB 9,396,152 thousand, down from RMB 10,027,159 thousand in 2023[17]. - Total liabilities decreased to RMB 1,316,964 thousand in 2024 from RMB 1,746,118 thousand in 2023, indicating improved financial stability[17]. - The company's equity attributable to shareholders was RMB 8,078,818 thousand, slightly down from RMB 8,279,316 thousand in 2023[17]. - Basic earnings per share for 2024 was RMB 0.10, a decrease from RMB 0.53 in 2023[17]. - The company reported a net profit of RMB 69.8 million for the year ended December 31, 2024, a decrease of 82.2% from RMB 391.6 million in 2023, resulting in a net profit margin drop to 3.5%[60]. - Other income and losses netted RMB 161.2 million in 2024, a decrease of 33.0% from RMB 240.5 million in 2023, primarily due to reduced interest income[52]. Market and Growth Strategy - The company provided a positive outlook for 2025, projecting a revenue growth of 10% to 12%[2]. - New product launches are expected to contribute an additional RMB 300 million in revenue next year[2]. - Market expansion plans include entering two new international markets by Q3 2025[2]. - The company aims to increase its market share by 3% in the next fiscal year through targeted marketing strategies[2]. - Future outlook includes potential market expansion and strategic partnerships to drive growth in the biopharmaceutical sector[12]. - The company plans to explore mergers and acquisitions to strengthen its market position and enhance its technological capabilities[12]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotechnology sector[104]. - Market expansion plans include entering three new international markets by the end of 2025, targeting a 10% market share in each[104]. Research and Development - The company is investing RMB 200 million in R&D for new technologies aimed at enhancing product offerings[2]. - The company is focusing on research and development in antibody-drug conjugates (ADC) and CAR-T cell therapies to enhance its product pipeline[12]. - The company has established a key technology platform for biotechnology drug quality research, having applied for and published 12 patents in this area[40]. - The company has enhanced its in vitro metabolism platform for small molecule drugs, establishing MSD detection methods for oligonucleotide drugs and mass spectrometry methods for ADC drugs, covering various drug types including antibodies and gene therapy products[28]. - The company is committed to advancing innovative experimental models and organoid applications, particularly in tumor research and new drug development[86]. - The company plans to develop innovative non-human primate disease models, focusing on aging-related diseases such as obesity and diabetes, to support drug screening and preclinical evaluation[86]. Operational Efficiency - The management highlighted a focus on improving operational efficiency, targeting a 5% reduction in costs by the end of 2025[2]. - The board of directors highlighted the successful implementation of cost-cutting measures, resulting in a 5% reduction in operational expenses[104]. - The company aims to enhance operational efficiency and service quality through various innovative initiatives[18]. - The company is actively seeking strategic investment opportunities to enhance product R&D, product portfolio, channel expansion, and cost control[74]. Compliance and Risk Management - Compliance with various legal and regulatory requirements is critical; failure to adhere could adversely affect the company's reputation, business, financial condition, and future prospects[87]. - The company has maintained compliance with all relevant laws and regulations, with no significant legal issues reported during the period[121]. - The company complies with anti-bribery and anti-corruption regulations to mitigate risks associated with bribery and corruption[196]. - The company faces risks from fluctuating international economic conditions and reduced investment in pharmaceutical innovation, which may impact international business revenue and foreign exchange losses[87]. Human Resources and Talent Management - The company has formed a professional service team of 2,652 members as of December 31, 2024, to improve management levels and service efficiency[44]. - The company is committed to maintaining effective communication with shareholders through various channels, including shareholder meetings and corporate communications[198]. - The company recruits and retains talented employees through a comprehensive training system aimed at enhancing technical expertise and service quality[195]. - The company has an urgent need for talent in management, technology, and marketing due to business expansion, with challenges in attracting and retaining qualified personnel amid rising competition and costs[87]. Shareholder and Financial Management - The company proposed a final dividend of RMB 0.03 per share for the fiscal year ending December 31, 2024, down from RMB 0.16 in 2023, resulting in a total proposed dividend amount of approximately RMB 22.39 million compared to RMB 119.98 million in the previous year[115]. - As of December 31, 2024, the company's distributable reserves amounted to RMB 822.2 million[126]. - The company has repurchased a total of 2,656,100 A-shares in 2024, with a total transaction amount of RMB 42,658,273.40 (excluding transaction fees)[128]. - The company has no significant investments, acquisitions, or disposals during the reporting period[70]. Client and Supplier Relations - The company served approximately 852 clients, including blue-chip pharmaceutical companies and small to medium-sized biotech firms as of December 31, 2024[187]. - The largest customer accounted for 2.87% of the group's total revenue, while the top five customers represented 11.76% of total revenue[199]. - The company has established stable relationships with numerous major suppliers located in China[191]. - There were no significant complaints from clients regarding the company's services or products during the reporting period[190].

智通财经4月29日电，截至发稿，药明康德(02359.HK)涨4.90%、凯莱英(03759.HK)涨2.71%、昭衍新药 (06127.HK)涨1.87%。 部分港股医药外包概念股走强 药明康德涨近5% ...

NO.1 赛力斯向港交所递交上市申请 4月28日，港交所文件显示，赛力斯集团股份有限公司向港交所提交上市申请书。今年3月底，赛力斯就宣布拟赴港上市，其彼时表示，发行H 股股票并上市是为了深入推进全球化战略布局，打造国际化资本运作平台，提高综合竞争力。H股募资将用于新能源汽车技术研发、海外市场 拓展及供应链优化。 点评：此次赴港上市旨在打造国际化资本运作平台，提高综合竞争力。H股募资将用于新能源汽车技术研发、海外市场拓展及供应链优化，这 将有助于赛力斯在全球新能源汽车市场中占据更有利的位置。 NO.2 昭衍新药一季度业绩同比扭亏为盈 4月28日，昭衍新药（HK06127，股价15.26港元）公布2025年第一季度业绩，公司实现营业收入约2.87亿元，同比减少11.54%；归属于上市公司 股东的净利润约4111.95万元，同比扭亏为盈；基本每股收益0.05元。公告称，净利增长主要系上年同期生物资产公允价值变动损失较多所致。 点评：尽管昭衍新药一季度营业收入有所下降，但净利润实现扭亏为盈，主要得益于上年同期生物资产公允价值变动损失的减少。这表明公司 在成本控制和运营效率方面取得了一定成效。 NO.3 耀才证券金融复 ...

前十大流通股东累计持有： 45893.43万股，累计占流通股比： 61.22%，较上期变化： 1356.72万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 冯宇霞 | 16716.06 | 22.30 | 不变 | | HKSCC NOMINEES LIMITED | 11897.56 | 15.87 | 0.05 | | 周志文 | 7472.60 | 9.97 | 不变 | | 顾晓磊 | 2042.05 | 2.72 | 不变 | | 香港中央结算有限公司 | 1771.98 | 2.36 | 1040.89 | | 左从林 | 1409.83 | 1.88 | 不变 | | 易方达医疗保健行业混合A | 1383.24 | 1.85 | 139.80 | | 华宝中证医疗ETF | 1238.63 | 1.65 | -2.89 | | 顾美芳 | 1032.20 | 1.38 | 不变 | | 全国社保基金一零九组合 | 929.28 | 1.24 | 新进 | | | 较上个报告期退出前十大股东有 | ...

Financial Performance - The company's operating revenue for Q1 2025 was RMB 287.34 million, a decrease of 11.54% compared to RMB 324.81 million in the same period last year[4]. - Net profit attributable to shareholders was RMB 41.12 million, a significant increase of 115.11% from a loss of RMB 272.22 million in the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 25.66 million, up 109.14% from a loss of RMB 280.67 million in the same period last year[4]. - Basic and diluted earnings per share were both RMB 0.05, reflecting an increase of 113.89% from a loss of RMB 0.36 per share in the same period last year[4]. - Operating profit for Q1 2025 was CNY 49,382,588.17, a significant recovery from a loss of CNY 293,008,274.73 in Q1 2024[23]. - Net profit for Q1 2025 reached CNY 41,119,465.25, compared to a net loss of CNY 273,363,603.07 in Q1 2024, marking a turnaround[23]. Cash Flow and Assets - The net cash flow from operating activities decreased by 45.69%, amounting to RMB 65.15 million compared to RMB 119.95 million in the previous year[4]. - Cash flow from operating activities in Q1 2025 was CNY 65,149,201.16, down from CNY 119,953,519.31 in Q1 2024[27]. - Cash inflow from investment activities in Q1 2025 was CNY 617,613,712.48, a substantial increase from CNY 111,453,520.72 in Q1 2024[27]. - Cash outflow from investment activities in Q1 2025 was CNY 951,573,490.95, compared to CNY 179,015,819.37 in Q1 2024, indicating increased investment[27]. - Cash and cash equivalents decreased from RMB 965.2 million to RMB 676.6 million, a decline of approximately 29.9%[17]. - The ending balance of cash and cash equivalents was $676,571,156.45, down from $2,865,314,156.35 at the beginning of the period[28]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 9.42 billion, a slight increase of 0.30% from RMB 9.40 billion at the end of the previous year[5]. - Total assets amounted to CNY 9,424,658,609.52, slightly up from CNY 9,396,152,610.45 in the previous period[20]. - Total current assets increased slightly from RMB 5.03 billion to RMB 5.06 billion, an increase of about 0.6%[18]. - Total current liabilities decreased from RMB 1.11 billion to RMB 1.10 billion, a reduction of about 0.8%[19]. - Non-current liabilities increased from RMB 206.4 million to RMB 217.8 million, an increase of approximately 5.7%[19]. - Total liabilities were CNY 1,315,452,686.46, showing a minor decrease from CNY 1,316,964,356.49[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,730[13]. - The company has a significant shareholder, Feng Yuxia, holding 22.30% of shares[13]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending[14]. Market Activity - The new signed orders amount to approximately RMB 430 million during the reporting period, with a total backlog of RMB 2.2 billion[15]. - The company is focused on expanding its market presence and enhancing its product offerings[15]. Non-Recurring Items - Non-recurring gains and losses amounted to RMB 15.46 million, with government subsidies contributing RMB 4.93 million[9]. - The net profit from laboratory services was a loss of RMB 41.34 million, a decline of 96.47% year-on-year, primarily due to intensified industry competition[5]. - The company reported a net gain of RMB 50.38 million from changes in the fair value of biological assets during the reporting period[5]. Return on Assets - The weighted average return on net assets increased by 3.86 percentage points to 0.51% compared to -3.35% in the previous year[4].

Financial Performance - The company's operating revenue for Q1 2025 was RMB 287.34 million, a decrease of 11.54% compared to RMB 324.81 million in the same period last year[7]. - Net profit attributable to shareholders for Q1 2025 was RMB 41.12 million, a significant increase of 115.11% from a loss of RMB 272.22 million in the previous year[7]. - Basic and diluted earnings per share for Q1 2025 were RMB 0.05, a turnaround from a loss of RMB 0.36 per share in the previous year, representing an increase of 113.89%[7]. - The weighted average return on equity increased by 3.86 percentage points to 0.51% compared to -3.35% in the same period last year[7]. - The net profit attributable to shareholders of the listed company increased by 115.11% compared to the same period last year, primarily due to significant losses from the fair value changes of biological assets in the previous year[16]. - The total comprehensive income for Q1 2025 was CNY 40,352,525.89, compared to a total comprehensive loss of CNY 272,499,809.53 in Q1 2024[30]. - Operating profit for Q1 2025 was CNY 49,382,588.17, a turnaround from an operating loss of CNY 293,008,274.73 in Q1 2024[28]. Cash Flow and Assets - The net cash flow from operating activities was RMB 65.15 million, down 45.69% from RMB 119.95 million in the same period last year[7]. - Cash and cash equivalents decreased to CNY 676,571,156.45 as of March 31, 2025, from CNY 965,203,128.59 at the end of 2024, a decline of 29.9%[22]. - The company’s cash flow management remains a priority, with a significant reduction in cash reserves noted[22]. - The cash and cash equivalents at the end of Q1 2025 were $676,571,156.45, a significant decrease from $2,865,314,156.35 in Q1 2024, reflecting a decline of about 76.4%[34]. - The net increase in cash and cash equivalents for Q1 2025 was -$288,629,929.27, contrasting with a positive increase of $11,667,128.38 in Q1 2024[34]. - The impact of exchange rate changes on cash and cash equivalents in Q1 2025 was -$1,154,223.86, compared to -$2,795,727.79 in Q1 2024, showing an improvement of approximately 58.7%[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,730[18]. - The top ten shareholders hold a total of 22.30% of shares, with the largest shareholder, Feng Yuxia, owning 167,160,633 shares[18]. - The company has not identified any related party relationships among the top ten shareholders, except for known familial connections[19]. Business Operations and Strategy - The laboratory services business contributed a net profit of RMB -41.34 million, a decline of 96.47% year-on-year, primarily due to increased industry competition[11]. - The company plans to enhance its laboratory services and financial management strategies to improve profitability amid competitive pressures[9]. - The company plans to focus on expanding its market presence and enhancing R&D efforts in the upcoming quarters[27]. - The company signed new orders worth approximately RMB 430 million during the reporting period, with a backlog of orders amounting to approximately RMB 2.2 billion at the end of the reporting period[20]. Non-Recurring Items - Non-recurring gains and losses for the reporting period amounted to RMB 15.46 million, with significant contributions from government subsidies and financial asset management[10][13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 25.66 million, an increase of 109.14% from a loss of RMB 280.67 million in the previous year[7]. - The non-recurring gains and losses totaled RMB 15,456,940.42, indicating significant impacts from various non-operating activities[14]. Costs and Expenses - Total operating costs for Q1 2025 were CNY 288,252,886.21, down from CNY 293,294,646.96 in Q1 2024, reflecting a reduction of 1.4%[27]. - R&D expenses for Q1 2025 amounted to CNY 23,027,883.99, slightly increasing from CNY 22,967,298.39 in Q1 2024[27]. - Other income for Q1 2025 was CNY 5,270,400.41, down from CNY 6,650,918.69 in Q1 2024[28]. - Investment income for Q1 2025 was CNY 1,235,855.96, a decline from CNY 6,972,038.25 in Q1 2024[28]. Market and Risk Awareness - The company emphasizes the need for investors to be aware of investment risks due to market environment changes and industry competition[20]. - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[20]. - The company did not apply new accounting standards or interpretations starting from 2025, indicating a stable accounting approach for the current reporting period[34].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 (2)關於召開2025年度第一季度業績說明會的公告 (3)關於續聘2025年度會計師事務所的公告 (4)第四屆董事會第十四次會議決議公告 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 附件為本公司於上海證券交易所網站刊登之 北京昭衍新藥研究中心股份有限公司 (1) 2025年第一季度報告 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年4月28日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 ...

港股医药股持续走弱，歌礼制药(01672.HK)跌超12%，药明生物(02269.HK)跌超5%，再鼎医药 (09688.HK)、昭衍新药(06127.HK)等跟跌。 ...

Core Viewpoint - The FDA has updated its policy to gradually eliminate mandatory animal testing for monoclonal antibody therapies and other drug developments, which has raised significant concerns in the industry, particularly for companies like Zhaoyan New Drug that rely heavily on animal testing [1][2]. Group 1: FDA Policy Changes - The FDA's new policy encourages the use of alternative methods such as computational models, organ-on-a-chip technology, and cross-species data integration to replace animal testing [1][4]. - The FDA's push for alternatives is seen as a potential milestone in drug development, which could impact not only domestic CRO companies but also global pharmaceutical research [4][5]. Group 2: Impact on Zhaoyan New Drug - Zhaoyan New Drug, which derives 95% of its revenue from non-clinical research, faces direct challenges as approximately 70% of its business involves animal testing [10][11]. - The company has a significant portion of its business (78%) from the domestic market, with only 22% from international markets, primarily the U.S. [10][11]. Group 3: Feasibility of Alternatives - The feasibility of AI and organ-on-a-chip technologies as alternatives to animal testing is being explored, with some advancements already noted in clinical trials [5][7]. - The FDA has previously approved a new drug based solely on organ-on-a-chip data, indicating that there is a pathway for these technologies to be integrated into drug development [7]. Group 4: Financial Implications - If animal testing is reduced, the cost of monkeys used in experiments may decline significantly, impacting Zhaoyan New Drug's investments in animal resources [14]. - The company's financial growth may increasingly depend on its clinical business, which is facing intense competition and declining profit margins [15].